Frazier Life Sciences Management, L.P. Immatics N.V. Transaction History
Frazier Life Sciences Management, L.P.
- $1.67 Billion
- Q4 2024
A detailed history of Frazier Life Sciences Management, L.P. transactions in Immatics N.V. stock. As of the latest transaction made, Frazier Life Sciences Management, L.P. holds 2,147,911 shares of IMTX stock, worth $11.5 Million. This represents 0.92% of its overall portfolio holdings.
Number of Shares
2,147,911
Previous 1,354,711
58.55%
Holding current value
$11.5 Million
Previous $15.5 Million
1.2%
% of portfolio
0.92%
Previous 0.83%
Shares
3 transactions
Others Institutions Holding IMTX
# of Institutions
93Shares Held
92.5MCall Options Held
313KPut Options Held
377K-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.6MShares$56.9 Million0.05% of portfolio
-
Wellington Management Group LLP Boston, MA10.4MShares$55.9 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY9.38MShares$50.4 Million2.23% of portfolio
-
Baker Bros. Advisors LP New York, NY7.28MShares$39.1 Million0.57% of portfolio
-
Rtw Investments, LP New York, NY6.54MShares$35.1 Million0.76% of portfolio
About Immatics N.V.
- Ticker IMTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,227,000
- Market Cap $409M
- Description
- Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...